West Oak Capital’s Gilead Sciences GILD Stock Holding History

West Oak Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$738	Hold	665	–	–	0.03%	148
2025 Q2	$737	Hold	665	–	–	0.03%	153
2025 Q1	$745	Hold	665	–	–	0.03%	158
2024 Q4	$614K	Hold	665	–	–	0.02%	170
2024 Q3	$558	Hold	665	–	–	0.01%	178
2024 Q2	$45.6K	Hold	665	–	–	0.02%	187
2024 Q1	$49K	Hold	665	–	–	0.02%	176
2023 Q4	$57K	Hold	665	–	–	0.03%	174
2023 Q3	$50K	Hold	665	–	–	0.02%	176
2023 Q2	$51.3K	Hold	665	–	–	0.02%	175
2023 Q1	$55.2K	Hold	665	–	–	0.03%	170
2022 Q4	$57K	Hold	665	–	–	0.03%	159
2022 Q3	$41K	Hold	665	–	–	0.02%	175
2022 Q2	$41K	Buy	665 +155	+30%	+$9.6K	0.02%	178
2022 Q1	$30K	Buy	510 +10	+2%	+$639	0.01%	199
2021 Q4	$36K	Hold	500	–	–	0.01%	202
2021 Q3	$35K	Hold	500	–	–	0.01%	204
2021 Q2	$34K	Hold	500	–	–	0.01%	207
2021 Q1	$32K	Sell	500 -35	-7%	-$2.26K	0.01%	204
2020 Q4	$31K	Sell	535 -275	-34%	-$16.6K	0.01%	199
2020 Q3	$51K	Sell	810 -250	-24%	-$17.3K	0.03%	165
2020 Q2	$82K	Hold	1,060	–	–	0.05%	144
2020 Q1	$79K	Buy	1,060 +245	+30%	+$16.9K	0.05%	137
2019 Q4	$53K	Sell	815 -249	-23%	-$16.2K	0.03%	172
2019 Q3	$67K	Hold	1,064	–	–	0.04%	163
2019 Q2	$72K	Hold	1,064	–	–	0.04%	161
2019 Q1	$69K	Hold	1,064	–	–	0.04%	160
2018 Q4	$66.6K	Hold	1,064	–	–	0.05%	152
2018 Q3	$82.2K	Hold	1,064	–	–	0.05%	156
2018 Q2	$75.4K	Hold	1,064	–	–	0.05%	160
2018 Q1	$80.2K	Sell	1,064 -1,727	-62%	-$137K	0.05%	163
2017 Q4	$200K	Sell	2,791 -1,895	-40%	-$144K	0.12%	113
2017 Q3	$380K	Buy	4,686 +20	+0.4%	+$1.53K	0.23%	97
2017 Q2	$330K	Buy	4,666 +32	+0.7%	+$2.13K	0.2%	101
2017 Q1	$315K	Buy	4,634 +467	+11%	+$32.8K	0.19%	98
2016 Q4	$298K	Sell	4,167 -282	-6%	-$21K	0.2%	94
2016 Q3	$352K	Buy	4,449 +32	+0.7%	+$2.6K	0.24%	93
2016 Q2	$368K	Sell	4,417 -100	-2%	-$8.88K	0.27%	87
2016 Q1	$415K	Hold	4,517	–	–	0.32%	85
2015 Q4	$457K	Hold	4,517	–	–	0.35%	79
2015 Q3	$444K	Buy	4,517 +50	+1%	+$5.55K	0.36%	76
2015 Q2	$523K	Sell	4,467 -50	-1%	-$5.46K	0.39%	70
2015 Q1	$443K	Buy	4,517 +3,720	+467%	+$378K	0.33%	80
2014 Q4	$75.1K	Hold	797	–	–	0.05%	134
2014 Q3	$84.8K	Hold	797	–	–	0.06%	126
2014 Q2	$66.1K	Hold	797	–	–	0.05%	139
2014 Q1	$56.5K	Sell	797 -350	-31%	-$27.4K	0.04%	139
2013 Q4	$86.1K	Buy	1,147 +65	+6%	+$4.53K	0.06%	123
2013 Q3	$68K	Hold	1,082	–	–	0.05%	131
2013 Q2	$55.5K	Buy	+1,082	New	+$56.4K	0.05%	133

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

West Oak Capital's GILD Position: Q3 2025 in Review

West Oak Capital held its Gilead Sciences (GILD) position steady in Q3 2025 at 665 shares worth $738. The position accounts for 0.03% of the portfolio, ranked #148.

West Oak Capital first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $614K in Q4 2024. 2,027 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

West Oak Capital held 665 shares of Gilead Sciences worth $738 as of Q3 2025.
West Oak Capital left its Gilead Sciences share count unchanged in Q3 2025.
Gilead Sciences made up 0.03% of West Oak Capital's portfolio in Q3 2025, its #148 holding.
West Oak Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
West Oak Capital's Gilead Sciences position peaked at $614K in Q4 2024.
2,027 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on West Oak Capital's 13F filing for Q3 2025, filed 3 Oct 2025.